» Articles » PMID: 33907043

Stress Increases MHC-I Expression in Dopaminergic Neurons and Induces Autoimmune Activation in Parkinson's Disease

Overview
Date 2021 Apr 28
PMID 33907043
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The expression of major histocompatibility complex class I (MHC-I), a key antigen-presenting protein, can be induced in dopaminergic neurons in the substantia nigra, thus indicating its possible involvement in the occurrence and development of Parkinson's disease. However, it remains unclear whether oxidative stress induces Parkinson's disease through the MHC-I pathway. In the present study, polymerase chain reaction and western blot assays were used to determine the expression of MHC-I in 1-methyl-4-phenylpyridinium (MPP)-treated SH-SY5Y cells and a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease mouse model. The findings revealed that MHC-I was expressed in both models. To detect whether the expression of MHC-I was able to trigger the infiltration of cytotoxic T cells, immunofluorescence staining was used to detect cytotoxic cluster of differentiation 8 (CD8) T cell infiltration in the substantia nigra of MPTP-treated mice. The results indicated that the presentation of MHC-I in dopaminergic neurons was indeed accompanied by an increase in the number of CD8 T cells. Moreover, in MPTP-induced Parkinson's disease model mice, the genetic knockdown of endogenous MHC-I, which was caused by injecting specific adenovirus into the substantia nigra, led to a significant reduction in CD8 T cell infiltration and alleviated dopaminergic neuronal death. To further investigate the molecular mechanisms of oxidative stress-induced MHC-I presentation, the expression of PTEN-induced kinase 1 (PINK1) was silenced in MPP-treated SH-SY5Y cells using specific small interfering RNA (siRNA), and there was more presentation of MHC-I in these cells compared with control siRNA-treated cells. Taken together, MPP-/MPTP-induced oxidative stress can trigger MHC-I presentation and autoimmune activation, thus rendering dopaminergic neurons susceptible to immune cells and degeneration. This may be one of the mechanisms of oxidative stress-induced Parkinson's disease, and implies the potential neuroprotective role of PINK1 in oxidative stress-induced MHC-I presentation. All animal experiments were approved by the Southern Medical University Ethics Committee (No. 81802040, approved on February 25, 2018).

Citing Articles

The interaction of tPA with NMDAR1 drives neuroinflammation and neurodegeneration in α-synuclein-mediated neurotoxicity.

Torrente D, Su E, Citalan-Madrid A, Schielke G, Magaoay D, Warnock M J Neuroinflammation. 2025; 22(1):8.

PMID: 39810216 PMC: 11731172. DOI: 10.1186/s12974-025-03336-3.


Myeloid antigen-presenting cells in neurodegenerative diseases: a focus on classical and non-classical MHC molecules.

Afify R, Lipsius K, Wyatt-Johnson S, Brutkiewicz R Front Neurosci. 2024; 18:1488382.

PMID: 39720231 PMC: 11667120. DOI: 10.3389/fnins.2024.1488382.


Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms.

Magnusen A, Pandey M Int J Mol Sci. 2024; 25(22).

PMID: 39596318 PMC: 11594573. DOI: 10.3390/ijms252212252.


Computational analysis of peripheral blood RNA sequencing data unravels disrupted immune patterns in Alzheimer's disease.

Anatolou D, Krokidis M AIMS Neurosci. 2024; 11(2):103-117.

PMID: 38988883 PMC: 11230858. DOI: 10.3934/Neuroscience.2024007.


The immune system in Parkinson's disease: what we know so far.

Roodveldt C, Bernardino L, Oztop-Cakmak O, Dragic M, Fladmark K, Ertan S Brain. 2024; 147(10):3306-3324.

PMID: 38833182 PMC: 11449148. DOI: 10.1093/brain/awae177.


References
1.
Jackson-Lewis V, Przedborski S . Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2007; 2(1):141-51. DOI: 10.1038/nprot.2006.342. View

2.
Spel L, Boelens J, van der Steen D, Blokland N, van Noesel M, Molenaar J . Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget. 2015; 6(34):35770-81. PMC: 4742140. DOI: 10.18632/oncotarget.5657. View

3.
Fiszer U, Mix E, Fredrikson S, Kostulas V, Olsson T, Link H . gamma delta+ T cells are increased in patients with Parkinson's disease. J Neurol Sci. 1994; 121(1):39-45. DOI: 10.1016/0022-510x(94)90154-6. View

4.
Papachroni K, Ninkina N, Papapanagiotou A, Hadjigeorgiou G, Xiromerisiou G, Papadimitriou A . Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem. 2007; 101(3):749-56. PMC: 3154646. DOI: 10.1111/j.1471-4159.2006.04365.x. View

5.
Matheoud D, Sugiura A, Bellemare-Pelletier A, Laplante A, Rondeau C, Chemali M . Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. Cell. 2016; 166(2):314-327. DOI: 10.1016/j.cell.2016.05.039. View